Tags

Type your tag names separated by a space and hit enter

Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
J Clin Hypertens (Greenwich). 2007 Mar; 9(3):187-95.JC

Abstract

This 12-week, randomized, double-blind, forced-titration study compared the efficacy of 3 angiotensin receptor blockers. Patients received olmesartan medoxomil 20 mg, losartan potassium 50 mg, valsartan 80 mg, or placebo once daily. At week 4, doses were titrated to 40, 100, and 160 mg once daily for olmesartan, losartan, and valsartan, respectively. At week 8, losartan was increased to 50 mg twice daily and valsartan increased to 320 mg once daily (olmesartan remained at 40 mg once daily). The primary end point was mean change from baseline in seated diastolic blood pressure (SeDBP) at week 8. All 3 medications significantly reduced mean SeDBP from baseline compared with placebo at weeks 4, 8, and 12 (P<.001). At week 8, olmesartan reduced mean SeDBP more than losartan (P<.001); more patients in the olmesartan medoxomil group achieved a blood pressure goal of <140/90 mm Hg (P<.001). Olmesartan did not reduce mean SeDBP significantly compared with valsartan, although more patients attained blood pressure goal with olmesartan (P=.031). At week 12, all agents lowered blood pressure equivalently.

Authors+Show Affiliations

Tulane University School of Medicine, New Orleans, LA 70005, USA. tgiles4@cox.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17341994

Citation

Giles, Thomas D., et al. "Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension." Journal of Clinical Hypertension (Greenwich, Conn.), vol. 9, no. 3, 2007, pp. 187-95.
Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187-95.
Giles, T. D., Oparil, S., Silfani, T. N., Wang, A., & Walker, J. F. (2007). Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. Journal of Clinical Hypertension (Greenwich, Conn.), 9(3), 187-95.
Giles TD, et al. Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187-95. PubMed PMID: 17341994.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. AU - Giles,Thomas D, AU - Oparil,Suzanne, AU - Silfani,Tonous N, AU - Wang,Antonia, AU - Walker,J Findlay, PY - 2007/3/8/pubmed PY - 2007/4/20/medline PY - 2007/3/8/entrez SP - 187 EP - 95 JF - Journal of clinical hypertension (Greenwich, Conn.) JO - J Clin Hypertens (Greenwich) VL - 9 IS - 3 N2 - This 12-week, randomized, double-blind, forced-titration study compared the efficacy of 3 angiotensin receptor blockers. Patients received olmesartan medoxomil 20 mg, losartan potassium 50 mg, valsartan 80 mg, or placebo once daily. At week 4, doses were titrated to 40, 100, and 160 mg once daily for olmesartan, losartan, and valsartan, respectively. At week 8, losartan was increased to 50 mg twice daily and valsartan increased to 320 mg once daily (olmesartan remained at 40 mg once daily). The primary end point was mean change from baseline in seated diastolic blood pressure (SeDBP) at week 8. All 3 medications significantly reduced mean SeDBP from baseline compared with placebo at weeks 4, 8, and 12 (P<.001). At week 8, olmesartan reduced mean SeDBP more than losartan (P<.001); more patients in the olmesartan medoxomil group achieved a blood pressure goal of <140/90 mm Hg (P<.001). Olmesartan did not reduce mean SeDBP significantly compared with valsartan, although more patients attained blood pressure goal with olmesartan (P=.031). At week 12, all agents lowered blood pressure equivalently. SN - 1524-6175 UR - https://www.unboundmedicine.com/medline/citation/17341994/Comparison_of_increasing_doses_of_olmesartan_medoxomil_losartan_potassium_and_valsartan_in_patients_with_essential_hypertension_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1524-6175&amp;date=2007&amp;volume=9&amp;issue=3&amp;spage=187 DB - PRIME DP - Unbound Medicine ER -